Women’s Health Diagnostics Market Size Worth USD 76.2 Billion by 2025

The global women’s health diagnostics market size is expected to reach USD 76.2 billion by 2025, according to a new report by Grand View Research, Inc. Rising adoption of point-of-care diagnostics and growing incidence of various chronic and lifestyle diseases are among the key factors stimulating the growth of the market. Besides this, introducing various awareness programs is also anticipated to work in favor the market during the forecast period. For instance, in 2014, the European Commission launched joint action for European Guide on Quality Improvement in Comprehensive Cancer Control.

Women’s health diagnostics is witnessing high growth due to increased funding from various organizations. For instance, in May 2015, Abcodia received funding of USD 8.0 million from Cambridge Innovative Capital, Scottish Equity Partners, Albion Ventures, and UCLB to launch Risk of Ovarian Cancer Algorithm (ROCA) test in the U.K. for early detection of ovarian cancer.

On the basis of end use, the market has been bifurcated into hospital & diagnostics centers and home. Hospitals and diagnostic centers accounted for a larger share in the market due to high number of visits to hospitals and more reliable detection.

The market in Asia Pacific is likely to witness significant growth over the coming years. The growth of the market can be attributed to increasing investments in healthcare, growing focus of international device manufacturers on strengthening their distribution networks within the region, and epidemiological shift from infectious diseases to chronic diseases within regional boundaries.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/womens-health-diagnostics-market

Further key findings from the report suggest:

• Increasing investments by governments and private bodies and rising disposable income are providing a push to the market
• Cancer accounted for the highest share in the market in 2017. The segment will register noteworthy growth during the forecast period owing to availability of early detection tests and government initiatives to tackle cancer
• Prenatal testing is estimated to be the fastest growing segment during the same period owing to rising prevalence of prenatal diseases, increasing maternal age, surging healthcare expenditure, and development of advanced diagnostic tests
• Geographically, North America was the leading revenue contributor to the women’s health diagnostics market in 2017. It is anticipated to maintain its dominance through 2025, thanks to widening base of diagnostic and imaging centers, mounting cases of cancer, growing awareness about fertility testing, and spiraling adoption of point-of-care testing devices
• Some of the key players are Siemens Healthcare Private Limited; Hologic, Inc.;GE Healthcare; F. Hoffmann-La Roche Ltd.; bioMérieux SA; Koninklijke Philips N.V; Abbott; Becton, Dickinson and Company, Quest Diagnostics, Inc.; and PerkinElmer, Inc.

Colposcopy Market Size Worth USD 293.6 Million by 2025

The global colposcopy market size is projected to reach USD 293.6 million by 2025, according to a new report by Grand View Research, Inc., rising at a CAGR of 7.0% during the forecast period. Increasing investments in the medical imaging industry and rising cervical cancer screening in developing countries are poised to trigger the growth of the market. Developing countries offer new investment avenues to global market giants. Developing healthcare infrastructure and expanding patient pool are rendering emerging countries promising destinations for global players in the market.

As per the findings of the World Health Organization, the number of new cervical cancer cases are estimated to reach 570,000 by end of 2018, accounting for 6.6% of total cancers related only to females. The number of deaths registered due to this type of cancer is higher in developing countries. It can be reduced by implementing a program which provides early diagnosis and effective treatment.

Governments in emerging economies are focusing on augmenting reach of cancer screening programs, which in turn is anticipated to boost the adoption of colposcopes. In addition, major market players are adopting advanced technologies by integrating various digital platforms with colposcopy equipment. Advent of high resolution imaging devices is expected to follow up integration, which is likely to replace conventional colposcopes, hence influencing the growth of the market.

Mergers and acquisitions and service portfolio expansion are some of the key strategies adopted by major players. For instance, in September 2016, DYSIS introduced an advanced imaging technique that has the ability to detect neoplasia and precancerous cells, which will help in diagnosing cancer. Prominent market players are also focusing on increasing their geographical reach.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/colposcopy-market

Further key findings from the report suggest:

• The video modality segment is projected to register the fastest growth during the forecast period
• The pelvic segment is poised to exhibit a CAGR of over 7.1% during forecast period
• The handheld segment is estimated to expand at a lucrative CAGR during the forecast period
• Asia Pacific is anticipated to exhibit a CAGR of about 8.0% during the forecast period owing to improvised healthcare infrastructure, rising disposable income, and investments from global market players
• Some of the key players in this market are Karl Kaps GmbH & Co. KG; Carl Zeiss; Cooper Surgical, Inc.; DYSIS Medical Ltd.; ATMOS Medizin Technik GmbH & Co. KG; OLYMPUS CORPORATION; McKesson Medical-Surgical Inc.; Ecleris S.R.L.; Optomic and Seiler Instrument Inc.

Disruptive Behavior Disorder Treatment Market Gain Worth USD 24.0 Billion By 2026

The global disruptive behavior disorder treatment market size is expected to reach USD 24.0 billion by 2026, according to a new report by Grand View Research, Inc. The market is projected to expand at a CAGR of 4.9% during the estimated period. Increasing cases of substance abuse across the globe are considered to be the key factors driving the market. Drug abuse is one of the major causes for acquiring oppositional defiant and conduct disorder as it enhances the symptoms for such conditions. Rising prevalence of mental disorders among children and teenagers is leading to increased awareness regarding the associated treatments, there by augmenting the market growth.

For instance, according to the Substance Abuse and Mental Health Services Administration (SAMHSA), globally, around 3.0% of children suffer from Oppositional Defiant Disorder (ODD) and around 8.0% of children suffer from Conduct Disorder (CD) per year. In recent times, majority of the parents of children aged between 5 and 14 years have undergone workshops and trainings for the treatment of above-mentioned conditions. Several hospitals, clinics, and institutes are organizing campaigns to create awareness about the relevant treatments among parents and physicians. For instance, the Child Mind Institute, Inc., organized a campaign named Speak Up for Kids, in May 2018, where children’s mental health issues and various treatments and policies related to these disorders were discussed. Therefore, such initiatives are expected to bolster the market growth over the forecast period.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/disruptive-behavior-disorders-market

Further key findings from the study suggest:

• In terms of revenue, oppositional defiant disorder segment is projected to ascend at a CAGR of 5.4% over the forecast period
• Increasing prevalence of such problems and awareness regarding their treatments will drive this segment
• Parenting therapy is expected to witness the fastest growth over the forecast period
• Frequent recommendation of parenting therapy by doctors, as it allows rapid recovery and is easy to follow, is expected to drive the segment
• Asia-Pacific market is expected to witness the fastest growth over the forecast period owing to the increasing cases of substance abuse
• Some of the key companies in the global disruptive behavior disorder treatment market are Highland Ridge Hospital, Lakeview Health, Boston Children's Hospital, INTEGRIS Health.

Antinuclear Antibody Test Market 2018 Share, Production and Consumption Analysis, Growth Factors, Brands Statistics and Overview by Top Manufacturers 2025

The global antinuclear antibody test market size is expected to reach USD 2.36 billion by 2025, according to a new report by Grand View Research, Inc. It is anticipated to expand at a CAGR of 12.5% over the forecast period. Rising adoption of ANA test coupled with government initiatives to treat autoimmune disorders is likely to drive the market. Furthermore, rising incidence of autoimmune disorders is projected to fuel the growth.

Antinuclear Antibody (ANA) testing is an important tool to diagnose and manage autoimmune diseases such as Systemic Lupus Erythematosus (SLE) and rheumatoid arthritis. According to the Lupus Foundation of America, at least 5 million people globally and around 1.5 million people in U.S. have a form of lupus. Around 16,000 new cases are registered every year. The disease mostly affects women of childbearing age. SLE accounts for almost 70% of all cases of lupus. The high prevalence of autoimmune disorders is one of the factors driving the market.

Extension of ANA from a test for SLE to a test for any autoimmune diseases has boosted the usage of antinuclear antibody testing. An increase in ANA demand may also be due to the factors such as expanded role of primary care physicians in healthcare delivery systems. In addition, rising R&D activities and government initiatives regarding early diagnosis of autoimmune disorders have triggered the demand for ANA tests.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/antinuclear-antibody-ana-test-market

Further key findings from the study suggest:

• Reagents and assay kits was the largest segment in 2017. It is likely to witness fastest growth over the forecast period due to wide usage and rise in a number of reagent rental agreements
• Immunofluorescence assay led the market in terms of market share in 2017 owing to superior sensitivity compared to other available techniques
• ELISA is expected to be the fastest growing segment over the forecast period. Increasing adoption of these tests is attributed to easy automation and handling without high level of operator skill
• Rheumatoid arthritis segment is projected to hold largest market share, mainly due to high prevalence of the disease
• North America was the largest region in terms of revenue in 2017, followed by Europe. Both are the most well-established regions in terms of the adoption of ANA testing and make up most of the existing market
• Asia Pacific is likely to be the fastest growing region over the forecast period due to unmet clinical needs and need for better diagnosis. Rising government initiatives and clinical research activities for advanced diagnostics are expected to further fuel growth
• Key players operating in the antinuclear antibody test market are Thermo Fisher Scientific Inc.; Alere Inc.; Bio-Rad Laboratories; Trinity Biotech PLC; Zeus Scientific, Inc.; Inova Diagnostics; Immuno Concepts; Erba Diagnostics, Inc.; Euroimmun AG; and Antibodies Inc.

North American Molecular Diagnostics Market Size, Share, Trends Analysis and Worth USD 8.10 Billion By 2025

The North America Molecular Diagnostics (MDx) market size is expected to reach USD 8.10 billion by 2025 expanding at a CAGR of 10.4% during the forecast period, according to a new report by Grand View Research, Inc. Rising incidence of long-term diseases, such as cancer, Cardiovascular Diseases (CVDs), neurological disorders, obesity, and diabetes, is expected to drive the North America MDx market.

According to the Population Reference Bureau, in U.S., the number of people aged 65 years and older is estimated to increase from 46 million in 2016 to around 98 million by 2060. Moreover, the data published by WHO states that the life expectancy is now exceeding to 80 years in most of the developed countries in the region. Thus, growing geriatric population is also likely to augment the market development. Aging characterizes the single most substantial risk factor for cancer development.

Based on the U.S. National Cancer Institute’s Surveillance Epidemiology and End Results (SEER) Database, 38% of women and 43% of men are estimated to develop cancer during their lifetime. Nearly two-thirds of all new cancer cases are diagnosed in individuals above the age of 65 years. This is where molecular diagnostics plays an important role as it has a tremendous impact on the management of suffering from chronic diseases such as cancer and Cardiovascular Diseases (CVDs). It is also vital for public health surveillance and detection.

Growing need for easy access to MDx has driven the Point-of-Care (PoC) market. One of the advantages offered by molecular diagnostics is that it can detect a disease even before the patient becomes symptomatic. PoC devices offer fast results, which, in turn, helps start treatments before the disease grows. With respect to infectious disease, early diagnosis can reduce pain, recovery time, and stop or slower the spread of disease.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/north-america-molecular-diagnostics-market

Further key findings from the study suggest:

• Reagents led the North America molecular diagnostics market in 2017 owing to high number of R&D activities pertaining to self-test and PoC products
• Central laboratories held the largest revenue share in 2017 due to factors, such as availability of skilled labor and well-established infrastructure
• PoC segment is estimated to witness lucrative growth over the forecast period owing to rising healthcare awareness and demand for bedside testing
• Infectious diseases segment was the largest application segment in 2017 owing to increased cases of tuberculosis, pneumonia, HIV, and others
• Oncology segment is estimated to witness the fastest growth during the forecast period as it involves a number of diseases with unmet clinical needs for improved therapeutics and diagnostics
• Key companies are Roche Diagnostics; Qiagen N.V.; Danaher Corp.; Hologic, Inc; Johnson & Johnson; Becton, Dickinson and Company; Abbott Laboratories; bioMérieux SA; Illumina, Inc.; Novartis AG; and Cepheid, Inc.

Breast Lesion Localization Methods New Research Report 2018

The global breast lesion localization methods market size is expected to reach USD 1.58 billion by 2025, according to a new report by Grand View Research, Inc. It is projected to witness a CAGR of 13.3% during the forecast period. Growing number of government and non-government reimbursement policies for the breast cancer diagnostics, biopsy, examination, and other medical procedures are estimated to increase the adoption of breast lesion localization methods. Moreover, high demand for better healthcare infrastructure and facilities due to rising prevalence of the target disease among women is expected to fuel the market growth.

It is more prevalent in women above the age of 50 years. Although it is majorly occurring in women, the male population has one in eight chances of being diagnosed with the target cancer. According to the WHO, almost 6.5% of all cancer-related deaths worldwide are caused by breast cancer. Increasing awareness level about breast cancer screening is expected to further enhance the market growth. For instance, in U.S., the Centre of Disease Control and Prevention’s National Breast and Cervical Cancer Early Detection Program (NBCCEDP) provides free access to timely breast and cervical diagnostic and screening services to the needy patients.

These screening programs include high-quality mammogram diagnosis, which involves breast X-rays, biopsies (if required), and an analytical judgment. Key companies, such as C.R. Bard, Inc.; Cianna Medical, Inc.; and Cook Medical, Inc. focus on business expansion in developing regions in an attempt to increase their market share. They are also adopting several other strategies, such as M&A and product launch. For instance, in October 2018, Cianna Medical, Inc. signed a merger agreement with Merit Medical Systems, Inc., in which the latter will provide clinical support for R&D to Cianna Medical, Inc. for commercializing new technologies in the market.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/breast-lesion-localization-methods-market

Further key findings from the study suggest:

• The global breast lesion localization methods market was valued at USD 580.7 million in 2017 and is expected to grow lucratively over the forecast period
• Wire-guided localization segment held the largest market share of 35.9% in 2017 owing to the presence of wide range of products and high adoption of this technique among end-users
• Radioisotope localization is expected to witness significant growth over the forecast period as it is an effective, safe, and widely used procedure for preoperative localization of non-palpable, suspicious breast lesions

• North America led the market with revenue of USD 209.96 million in 2017. The presence of key manufacturers in U.S., established healthcare infrastructure, and high adoption of localization devices are the factors responsible for its largest share
• Asia Pacific is expected to witness the fastest CAGR of 15.3% during the forecast period due to increasing demand for breast conserving surgery.

Capillary Blood Collection Devices Market Size, Revenue, Application, Types, Trends and Future Scope to 2018-2025

The global capillary blood collection devices market size is expected to reach USD 1.75 billion by 2025, according to a new report by Grand View Research, Inc., progressing at a CAGR of 5.4% during the forecast period. Increasing incidence of chronic, infectious and autoimmune diseases are some of the major factors propelling market growth owing to rising number of blood tests globally. Capillary blood draw technique has been most widely used for glucose and hemoglobin testing in clinics and hospitals. Ease of usage and minimally invasive nature also makes it ideal for home care diagnosis and testing, thereby boosting the market’s growth potential.The use of this technique in conjugation with PoC diagnostics has become the chosen mode of testing in remote and ambulatory health settings.

Blood gas detection, leukocyte & metabolite count, biomarker, nucleic acid, blood glucose, ferritin, lactate, effect of vitamin K-antagonist, and heavy metal ions analysis is commonly done using these samples. Thus, with rising adoption of rapid PoC diagnostics, usage of these devices is anticipated to increase in the near future.

Chronic diseases are a global healthcare problem with over half of the adult population in the U.S. suffering from chronic diseases, which contribute to over 75% of the total healthcare cost in the nation. Thus, rising number of infectious and chronic diseases creates a huge demand for diagnostic testing, thereby propelling growth of these collection devices.

Capillary blood draw technique is most often used in case of pediatric patients as it is difficult to draw venous and arterial blood from infants. Capillary blood draw is preferred in many ICU settings as patients lose large amount of blood during surgeries. Other blood drawing techniques are more invasive and might result in delays in the healing process or pose a risk of contamination. Ease of usage and effectiveness is another factor facilitating the use of these devices for home care diagnosis and testing, typically in case of diabetics.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/capillary-blood-collection-devices-market

Further Key Findings From the Report Suggest:

• Plastic devices held the largest market share in 2017 owing to their lightweight, cost-effective, and biocompatible nature coupled with extensive usage in medical devices
• Durability, non-porous nature, and impermeability are boosting the demand for glass devices
• Plastic and glass based collection devices are anticipated to dominate the market throughout the forecast horizon during the forecast period due to their extensive use in the manufacture of medical devices and other related products.
• North America will lead the market throughout the forecast period owing to existence of large number of major market players and high incidence of chronic and infectious diseases
• The Asia Pacific market is expected to rise at the highest CAGR during the same period. High population along with rising incidence of chronic diseases such as cancer and diabetes are the major factors contributing to the growth of the regional market

• Some of the major players are Becton, Dickinson and Company; NIPRO Europe Corporation; Sarstedt AG & Co; Thermo Fisher Scientific Inc.; Terumo Medical Corporation; B Braun Melsungen AG; Kabe Labortechnik GmbH; Greiner Bio One International GmbH; Cardinal Health; and Owen Mumford Ltd.

Hematology Diagnostics Market by Department, Enterprise, Delivery Mode, Vendor & End User 2018

The global hematology diagnostics market size is expected to reach USD 9.39 billion by 2025, according to a new report by Grand View Research, Inc. It is anticipated to register a CAGR of 5.85% over the forecast period. Increasing prevalence of blood disorders coupled with adoption of automated testing processes are projected to propel the market growth.\

Automation of hematology diagnostics process have led to reduced turnaround time thereby accelerating the overall treatment regimen. Furthermore, automation has also led to reduced administrative errors and overall costs of diagnostic tests. Thus, it is expected to boost growth of the hematology testing market in the forthcoming years.

Dominance of hematology analyzers can be attributed to the presence of fully-automated analyzers which are objective, have high-throughput, and are cost-effective. Furthermore, these hematology analyzers can also detect atypical results and can improve measurable parameters such as red cell distribution width, platelet distribution, Reticulocyte (RET) counts, and nucleated red cells counts.

The advent of Point-Of-Care (PoC) hematology testing devices has led to improved diagnostic and patient outcomes. These devices are user-friendly and are available for use outside the hospital settings. This is anticipated to increase the acceptability and accessibility of hematology testing which, in turn, is anticipated to propel market growth.

Product recall and intense market competition leading to price wars are anticipated to hinder market growth. In 2018, Becton Dickinson (BD) and Company recalled Vacutainer EDTA Blood Collection Tubes owing to chemical interference with certain tests. This recall was classified as Class I recall, the most serious type of recall, by the Food and Drug Administration (FDA), thereby indicating that the use of these devices may cause serious injuries or death. Such product recalls can negatively affect the market growth.

 To request a sample copy or view summary of this report, click the link below: 

https://www.grandviewresearch.com/industry-analysis/hematology-diagnostics-market

Further key findings from the report suggest:

• Consumables emerged as the largest segment owing to increasing testing and diagnosis of blood disorders
• Diagnostic labs segment is projected to expand at a lucrative CAGR over the forecast period owing to high prevalence of blood disorders
• North America held the dominant market share in 2017 owing to favorable reimbursement scenario and presence of sophisticated technological facilities
• Asia Pacific is projected to witness swift growth during the forecast period owing to the rising healthcare expenditure coupled with focus on quality healthcare infrastructure
• Few of the key players in hematology testing market include Beckman Coulter, Inc.;Abbott Laboratories; F. Hoffmann-La Roche Ltd.; Siemens Healthineers; Mindray Medical International Limited; and Sysmex Corporation.

Molecular diagnostics market growth is expected to reach over USD 17.9 billion by 2024

Increasing prevalence of infectious diseases including human papillomavirus and influenza is expected to be the primary driving force for the growth of the molecular diagnostics market. In the underdeveloped regions of Africa and Nigeria, other infections, such as HIV and tuberculosis, are soaring at a high growth rate since the last few years. This is estimated to increase the demand for early and accurate diagnostic techniques to curb their growth rate.

Prenatal genetic testing, performed for the purpose of early detection of abnormalities that develop in the fetuses of carrier parents, is also expected to widen the client base for the molecular diagnostics market. Moreover, the high adoption of unhealthy lifestyles further resulting in a large patient count afflicted with chronic diseases, such as diabetes and cardiovascular disorders, is also projected to positively impact the growth.

View summary of this report, Click Here 

Further key findings from the study suggest:

• The overall market is dominated by reagents with revenue generation of over USD 2.3 billion in 2015 owing to their elevated usage rates. Reagents are key products used in academic and research institutes to perform various molecular biology protocols further contributing toward the dominance of this segment.
• Instruments, such as PCR and next generation sequencing platforms, are being widely preferred by central laboratories and diagnostic institutes due to the rapid nature of these tests in delivering quick & reliable results and the high volume of diagnostic procedures in this segment. Thus, this segment is expected to maintain a constant growth at a CAGR of around 9.0%.
• Central laboratories led the global molecular diagnostics market by test location with revenue generation of around USD 4.0 billion in 2015 owing to their established base in the remote and developing regions
• On the other hand, the point of care devices segment witnessed the fastest growth with a CAGR of over 14.0%. The associated advantages include the user-friendly nature of these tests and quick healthcare delivery, which are estimated to propel the molecular diagnostics market.
• Infectious diseases held the largest share of over USD 2.9 billion in 2015. Molecular testing tools provide clinicians with better alternatives to detect countless infectious bacteria, virus, and pathogens in short time while delivering highly accurate results. Initiatives led by organizations, such as the WHO, in conducting diagnostic programs in regions with high risk areas is estimated to be a high rendering driver.
• The oncology segment is expected to exhibit a CAGR of around 13.0% over the forecast period. Rising awareness levels among people as well as healthcare professionals for cancer diagnosis is a key attribute propelling the market growth.
• The PCR segment dominated the market with revenue generation of over USD 2.6 billion in 2015, attributable to the growing applications of multiplex PCR over the conventional PCR procedure and the introduction of easy-to-use PCR handling kits.
• North America was observed to be the largest regional segment in 2015 with a share of over 45.0%. Key factors contributing toward the large share are well-established healthcare infrastructure, rising healthcare spending, increasing awareness levels among patients, and expansion of R&D activities related to drug discovery and development.
• Asia Pacific is identified as a lucrative segment with a CAGR of approximately 17.0% over the forecast period. Rising demand for improved diagnostic technologies employed for the prevention of epidemics, unaddressed clinical needs, and recent activities by key players targeting expansion in this region are the major factors supporting the market growth.
• Some of the major players include Novartis AG (Grifols), Siemens Healthcare GmbH, Bio-Rad Laboratories, Inc., Alere, Inc., Danaher Corporation, bioMérieux SA, Sysmex Corporation, Becton, Dickinson and Company, Johnson & Johnson Services, Inc., Bio-Rad Laboratories, Inc., Bayer AG, Qiagen, Hologic, Inc. (Gen Probe), Cepheid, F. Hoffmann-La Roche Ltd, and Dako
• The key players are advancing strategic collaborations with major technology-based companies & diagnostic centers and expanding into the developing regions in an attempt to increase their market share and attain stability

Click Here For Access Full Report : https://goo.gl/jivUWM

Non-invasive prenatal testing market is anticipated to reach USD 5.5 billion by 2025

Evolution of prenatal testing in the form of noninvasive tests that can serve as an intermediate step between serum screening and invasive diagnostic testing to determine the likelihood of fetal abnormality is expected to drive growth in the reproductive genetics industry over the forecast period.

In addition, presence of payers such as Anthem and Blue Shield of California that have endorsed cfDNA-based Noninvasive Prenatal Testing (NIPT) for trisomies 13, 18, and 21 is expected to impact the adoption rate of these tests, thereby resulting in increased revenue generation.

However, the projected NIPT-related price erosion in this market is expected to continue, thus intensifying competition amongst the operating participants, but restraining revenue generation to a certain extent.

View summary of this report, Click Here 

Further Key Findings fromthe Report Suggest:

• The market is segmented on the basis of the tests carried out during the gestation period as 0-12 weeks, 13-24 weeks, and 25-36 weeks
• 13-24 weeks accounted for the largest share owing to the presence of maximum number of the tests carried out in this phase of pregnancy
• High & average risk pregnancy held the larger share owing to presence of favorable payer reimbursement in this segment
• Rising awareness pertaining to the prevention and screening of chromosomal anomalies, such as Down Syndrome is another factor anticipated to impact adoption
• Asia Pacific is expected to register fastest year-on-year progress owing to the gradually increasing average maternal age, & increasing incidence of chromosomal aneuploidies
• Some of the key players operating the market space include Natera, Inc;Illumina, Inc; Sequenom; Roche (Ariosa Diagnostics); Quest Diagnostics; and LabCorp
• One of the key trends followed by companies includes licensing of the test to other labs and generating significant revenue by collecting royalty payments

Click Here For Access Full Report : https://goo.gl/Y3Sd5N

Molecular diagnostics market size is expected to reach over USD 17.9 billion by 2024

Global molecular diagnostics market is expected to reach over USD 17.9 billion by 2024, based on a new report by Grand View Research, Inc. Increasing prevalence of infectious diseases including human papillomavirus and influenza is expected to be the primary driving force for the growth of the molecular diagnostics market. In the underdeveloped regions of Africa and Nigeria, other infections, such as HIV and tuberculosis, are soaring at a high growth rate since the last few years. This is estimated to increase the demand for early and accurate diagnostic techniques to curb their growth rate.

Prenatal genetic testing, performed for the purpose of early detection of abnormalities that develop in the fetuses of carrier parents, is also expected to widen the client base for the molecular diagnostics market. Moreover, the high adoption of unhealthy lifestyles further resulting in a large patient count afflicted with chronic diseases, such as diabetes and cardiovascular disorders, is also projected to positively impact the growth.

View summary of this report, Click Here

Further key findings from the study suggest:

• The overall market is dominated by reagents with revenue generation of over USD 2.3 billion in 2015 owing to their elevated usage rates. Reagents are key products used in academic and research institutes to perform various molecular biology protocols further contributing toward the dominance of this segment.
• Instruments, such as PCR and next generation sequencing platforms, are being widely preferred by central laboratories and diagnostic institutes due to the rapid nature of these tests in delivering quick & reliable results and the high volume of diagnostic procedures in this segment. Thus, this segment is expected to maintain a constant growth at a CAGR of around 9.0%.
• Central laboratories led the global molecular diagnostics market by test location with revenue generation of around USD 4.0 billion in 2015 owing to their established base in the remote and developing regions
• On the other hand, the point of care devices segment witnessed the fastest growth with a CAGR of over 14.0%. The associated advantages include the user-friendly nature of these tests and quick healthcare delivery, which are estimated to propel the molecular diagnostics market.
• Infectious diseases held the largest share of over USD 2.9 billion in 2015. Molecular testing tools provide clinicians with better alternatives to detect countless infectious bacteria, virus, and pathogens in short time while delivering highly accurate results. Initiatives led by organizations, such as the WHO, in conducting diagnostic programs in regions with high risk areas is estimated to be a high rendering driver.
• The oncology segment is expected to exhibit a CAGR of around 13.0% over the forecast period. Rising awareness levels among people as well as healthcare professionals for cancer diagnosis is a key attribute propelling the market growth.
• The PCR segment dominated the market with revenue generation of over USD 2.6 billion in 2015, attributable to the growing applications of multiplex PCR over the conventional PCR procedure and the introduction of easy-to-use PCR handling kits.
• North America was observed to be the largest regional segment in 2015 with a share of over 45.0%. Key factors contributing toward the large share are well-established healthcare infrastructure, rising healthcare spending, increasing awareness levels among patients, and expansion of R&D activities related to drug discovery and development.
• Asia Pacific is identified as a lucrative segment with a CAGR of approximately 17.0% over the forecast period. Rising demand for improved diagnostic technologies employed for the prevention of epidemics, unaddressed clinical needs, and recent activities by key players targeting expansion in this region are the major factors supporting the market growth.
• Some of the major players include Novartis AG (Grifols), Siemens Healthcare GmbH, Bio-Rad Laboratories, Inc., Alere, Inc., Danaher Corporation, bioMérieux SA, Sysmex Corporation, Becton, Dickinson and Company, Johnson & Johnson Services, Inc., Bio-Rad Laboratories, Inc., Bayer AG, Qiagen, Hologic, Inc. (Gen Probe), Cepheid, F. Hoffmann-La Roche Ltd, and Dako
• The key players are advancing strategic collaborations with major technology-based companies & diagnostic centers and expanding into the developing regions in an attempt to increase their market share and attain stability

To get full details at: https://goo.gl/WJIfeV